FAQ
What we’re building, how the clinical and consumer brands differ, and how to engage.
Microbiome-as-a-Drug is the approach of treating defined, functional gut microbiota — and their metabolites — as a controllable therapeutic class rather than a supplement. It pairs an industrialized, standardized manufacturing process (FMT 3.0, under P2 + GMP) with a proprietary strain library and AI-native discovery, so that microbiome interventions can be dosed, traced and studied like a medicine.
FMT 3.0 is our freeze-dried, capsule-based generation of fecal microbiota transplantation, first introduced by aFMT in 2023. Compared with earlier slurry (1.0) and frozen (2.0) approaches, FMT 3.0 targets a cleaner, standardized, room-stable product with consistent dosing — manufactured under P2 + GMP with triple-encapsulation for strain viability.
They are two brands of JCY Bio. aFMT is our clinical brand — industrialized FMT 3.0 delivered to hospitals and research partners, for use within qualified medical settings. SereneSwift is our consumer brand — a medical-grade gut-brain probiotic positioned as a food/supplement, not a drug. Both are grounded in the same underlying microbiome science.
No. SereneSwift is a food/supplement category product — not intended to diagnose, treat, cure or prevent any disease. Individual experiences vary. Clinical claims and references on this site refer to our clinical brand aFMT.
The gut and brain are in continuous, two-way communication via neural, immune and metabolic signals. Friendly gut bacteria help produce and regulate precursors of neuro-active molecules, generate beneficial metabolites such as short-chain fatty acids, and contribute to a balanced microbial environment — the foundation many people associate with feeling steady. SereneSwift is designed to support this everyday balance; it is not a treatment for mood disorders.
Every clinical case narrative on /evidence/cases is de-identified and carries a cited source (peer-reviewed journal, expert consensus, or internal study). Patient data is reduced to age band and initials only; full patient records never leave the clinical setting and never enter this site.
Donors are sourced from a young, healthy university-age population (18–25) and screened against a strict, multi-stage protocol covering more than 120 medical items. Less than 2% of candidates qualify, and donors are subject to ongoing dynamic monitoring and full traceability of donations.
For clinical collaboration, FMT 3.0 supply or research partnerships, use our Partner with us page or Contact form and indicate your institution and area of interest. We work with qualified medical settings and academic centers.
Use the Partner & Invest page and submit a request, indicating Investor — request brief / data room. A gated data room is on the roadmap; today we share materials on request with qualified parties.